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Background: We aimed to perform a systematic search and meta-analysis to evaluate
the prognostic value of on-admission liver function tests and pre-existing liver diseases
on the clinical course of coronavirus disease 2019 (COVID-19).
Methods: The study was registered on PROSPERO (CRD42020182902). We searched
five databases between 01/01/2020 and 04/23/2020. Studies that reported on
liver-related comorbidities and/or laboratory parameters in patients with COVID-19
were included. The main outcomes were COVID-19 severity, intensive care unit (ICU)
admission, and in-hospital mortality. Analysis of predictive models hierarchical summary
receiver-operating characteristic (HSROC) was conducted with a 95% confidence
interval (CI).
Results: Fifty studies were included in the meta-analysis. High specificity was reached
by acute liver failure associated by COVID-19 (0.94, 95% CI: 0.71–0.99) and platelet
count (0.94, 95% CI: 0.71–0.99) in the case of mortality; chronic liver disease (CLD)
(0.98, 95%CI: 0.96–0.99) and platelet count (0.82, 95%CI: 0.72–0.89) in the case of ICU
requirement; and CLD (0.97, 95%CI: 0.95–0.98), chronic hepatitis B infection (0.97, 95%
CI: 0.95–0.98), platelet count (0.86, 95% CI: 0.77–0.91), and alanine aminotransferase
(ALT) (0.80, 95% CI: 0.66–0.89) and aspartate aminotransferase (AST) (0.84, 95% CI:
0.77–0.88) activities considering severe COVID-19. High sensitivity was found in the case
of C-reactive protein (CRP) for ICU requirement (0.92, 95% CI: 0.80–0.97) and severe
COVID-19 (0.91, 95% CI: 0.82–0.96).
Conclusion: On-admission platelet count, ALT and AST activities, CRP concentration,
and the presence of acute and CLDs predicted the severe course of COVID-19. To
Váncsa et al. Liver Involvement in COVID-19
highlight, pre-existing liver diseases or acute liver injury associated by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection plays an important role in
the prediction of mortality.
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INTRODUCTION
In December 2019, a local outbreak of pneumonia caused by a
novel coronavirus, namely, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China.
In most cases, coronavirus disease 2019 (COVID-19) is an
acute, self-limiting disease with a relatively brief period of
symptoms and resolution within days. However, it can reach
in-hospital mortality of 3–7% (1), which can result from
massive alveolar damage, consequential acute respiratory distress
syndrome (ARDS), respiratory failure, septic shock, or multiple
organ dysfunction (2, 3).
It is important to explore the prognostic factors, which have a
significant impact on the disease course, given the rapid spread
of COVID-19 and its high mortality rate. The detrimental effects
of hypertension, cardiovascular diseases, kidney disease, and
diabetes mellitus on the disease course are already proven (4–
6). Due to the limited number of reports on COVID-19 with
underlying chronic liver disease (CLD) to date, the impact of
pre-existing liver pathologies on COVID-19 progression and
outcomes is unknown.
Although coronaviruses cause the worst damage on the lungs,
studies suggest that other organs, such as the liver, intestines,
heart, and central nervous system, could also be affected (7–
11). In COVID-19, almost half of the hospitalized patients have
various degrees of liver test abnormalities, and liver impairment
was also observed in 14–53% of the patients (12).
We aimed to appraise the currently available literature of
confirmed SARS-CoV-2 infections critically and to investigate
the prognostic value of on-admission liver function and liver
conditions on the clinical course of COVID-19.
MATERIALS AND METHODS
Our systematic review and meta-analysis was planned and
reported according to the PRISMA (Preferred Reporting Items
for Systematic Reviews and Meta-Analyses) 2009 Statement (13)
(Supplementary Table 1). This study was registered in advance
on PROSPERO under registration number CRD42020182902
(see https://www.crd.york.ac.uk/prospero).
Search and Selection
A systematic search was conducted by two independent reviewers
(LS and NZ) to identify all the relevant records on the prognostic
value of liver impairment in COVID-19 patients published from
January 1, 2020 to April 23, 2020. The search was performed in
MEDLINE via PubMed, Embase, Scopus, Cochrane Library, and
Web of Science with the terms (“covid 19”) OR (“Wuhan virus”)
OR (“coronavirus”) OR (“2019 nCoV”) OR (“SARS-CoV-2”)
without language or other restrictions. References were managed
by the EndNote X9 software (Clarivate Analytics, Philadelphia,
PA, USA). Following the removal of duplicates, title and abstract
screening were performed by two independent reviewers (PJH
and NV) to identify potentially eligible articles. Disagreements
were reviewed by a third review author (KJ) and resolved by
consensus. The reference lists of the relevant articles were hand-
searched, and additional eligible records were included.
We included studies without any restriction that reported
on (C) liver diseases (as defined by eligible studies) and/or on-
admission liver function tests in (P) patients with confirmed
COVID-19. Concerning the laboratory parameters, cut-off values
predefined by the individual studies were used for abnormal
parameters (O). The assessed outcomes were as follows: in-
hospital mortality, severe SARS-CoV-2 infection defined by
eligible studies, and intensive care unit (ICU) requirement
defined by eligible studies. Severity of COVID-19 was classified
according to the guidelines on the Diagnosis and Treatment of
COVID-19 issued by the National Health Commission of China
(14). Details are presented in Supplementary Table 2. Studies
with a sample size of fewer than 15 subjects were excluded
because of the small effect size. When there were multiple
publications using data with overlapping study populations, we
included the one with a greater sample size.
Data Extraction and Outcomes
Relevant data were independently extracted from studies by
review authors ZRD and FD. These included: first author, year
of publication, country of origin, time interval and place of the
study, study design, basic characteristics of the study population
(age, percentage of females, and size of the study groups),
the proportion of event (in-hospital mortality, severe SARS-
CoV-2 infection, and need for ICU care) in patients with and
without liver impairment, time of measurement for outcomes,
and serum laboratory parameters [total bilirubin, albumin,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase
(GGT), platelet count, international normalized ratio (INR),
lactate dehydrogenase (LDH), and C-reactive protein (CRP)],
predefined cut-off values, and information for risk of bias
assessment. Extracted data were validated by MF and SK.
Statistical Analysis
Calculations were performed by Stata 15 data analysis and
statistical software (StataCorp LLC, College Station, TX, USA).
The first preference was the analysis of hierarchical summary
receiver-operating characteristic (HSROC) predictive models
with 95% confidence interval (CI) when at least five articles
were available for the given outcome. The area under the curve
(AUC) values and their 95% CIs for each prognostic factor and
outcome were collected, and a meta-analysis using the random
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FIGURE 1 | PRISMA flowchart.
effect model to gain pooled AUC estimates with 95% CI was
performed. Second preference in case of dichotomous variables
(mortality, severe vs non-severe, and ICU vs. non-ICU) was the
calculation of odds ratios (OR) with a 95% CI. A p < 0.05 was
considered statistically significant.
Heterogeneity was tested with I² and χ² tests. As suggested by
the Cochrane Handbook, I2 values were interpreted as moderate
(30–60%), substantial (50–90%), and considerable (75–100%)
heterogeneity (15). A p < 0.10 was considered significant. Forest
plots and HSROC curves were used to present the results of
the meta-analyses. Publication bias was checked by Egger’s test
(alpha = 0.1) when at least 10 studies were available (16). A
p< 0.1 was chosen because of the low number of studies included
in our analyses, since it can determine a significant heterogeneity
with greater certainty (17).
Assessment of Risk of Bias
Bias assessment was performed by two authors independently
(PHa and TH) using the modified Quality In Prognosis Studies
(QUIPS) assessment tool (18). Disagreements were resolved by a
third investigator (GP). Details of the used QUIPS tool are shown
in the footnote of Supplementary Table 5.
Protocol Deviation
We waived the need for data extraction and analysis regarding
the continuous variables and Funnel plots after statistical
consultation as it did not provide additional value.
RESULTS
Overall, 19,609 records were identified through the
comprehensive search, from which 1,647 full texts were
reviewed, and 50 studies were included in the qualitative and
quantitative syntheses. The selection process is presented in
Figure 1.
Basic characteristics of the included studies are shown in
Table 1 and Supplementary Table 3. Detailed eligibility criteria
for each included study are presented in Supplementary Table 4.
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TABLE 1 | Basic characteristics of the included studies.
Study Country Cohort type Total number of
patients (female %)
Age (year)‡ Outcome(s)
Definition Event number
(event rate %)
Cai et al. (19) China Retrospective 298 (51) 48 Severe COVID-19 58 (19)
Cai et al. (20) China Retrospective 318 (NR) NR Severe COVID-19 85 (27)
Cao et al. (21) China Prospective 102 (48) 54 Mortality 17 (17)
Chen et al. (22) China Retrospective 21 (19) 56 Severe COVID-19 11 (52)
Chen et al. (4) China Retrospective 1,590 (43) NR Mortality 50 (3)
Chen et al. (23) China Retrospective 274 (38) 62 Mortality 113 (41)
Chen et al. (24) China Retrospective 203 (38) 74 Mortality 19 (9)
Chen et al. (25) China Retrospective 48 (23) 65 ICU admission 17 (35)
Colombi et al. (26) Italy Retrospective 236 (25) 68 ICU admission 108 (46)
Du et al. (27) China Retrospective 109 (32) 71 ICU admission 51 (47)
Fan et al. (28) Singapore Retrospective 67 (45) 42 ICU admission 9 (13)
Fan et al. (29) China Retrospective 148 (NR) NR Mortality 1 (1)
ICU admission 10 (7)
Feng et al. (30) China Retrospective 476 (43) 53 ICU admission 70 (15)
Goyal et al. (31) USA Retrospective 393 (39) 62 ICU admission 130 (33)
Grein et al. (32) Multiple† Retrospective 53 (25) 64 ICU admission 34 (64)
Guan et al. (5) China Retrospective 1,099 (42) 47 Severe COVID-19 173 (16)
Guan et al. (33) China Retrospective 1,590 (43) 49 ICU admission 99 (6)
Severe COVID-19 254 (16)
Huang et al. (34) China Prospective 41 (27) 49 ICU admission 13 (32)
Ji et al. (35) China Retrospective 202 (44) 45 Severe COVID-19 39 (19)
Ji et al. (36) China Retrospective 208 (44) 44 Severe COVID-19 40 (19)
Li et al. (37) China Retrospective 548 (49) 60 Severe COVID-19 269 (49)
Liu et al. (38) China Retrospective 383 (58) 46 Mortality 49 (13)
Qi et al. (39) China Prospective 70 (NR) NR Severe COVID-19 3 (4)
Qian et al. (40) China Retrospective 324 (49) 51 Severe COVID-19 26 (8)
Qin et al. (41) China Retrospective 452 (48) 58 Severe COVID-19 286 (63)
Richardson et al. (42) USA Retrospective 2,634 (NR) NR Mortality 553 (21)
Ruan et al. (43) China Retrospective 150 (32) NR Mortality 68 (45)
Shen et al. (44) China Retrospective 119 (53) 49 Severe COVID-19 20 (17)
Shi et al. (45) China Retrospective 487 (47) 46 Severe COVID-19 49 (10)
To et al. (46) China Retrospective 23 (43) 62 Severe COVID-19 10 (43)
Tu et al. (47) China Retrospective 174 (55) NR Mortality 25 (14)
Wan et al. (48) China Retrospective 135 (47) 47 Severe COVID-19 40 (30)
Wan et al. (49) China Retrospective 123 (46) NR Severe COVID-19 21 (17)
Wang et al. (50) China Retrospective 339 (51) 69 Mortality 65 (19)
Wang et al. (51) China Retrospective 55 (60) 49 Severe COVID-19 2 (4)
Wang et al. (52) China Retrospective 69 (54) 42 ICU admission 14 (20)
Wu et al. (53) China Retrospective 280 (46) 43 ICU admission 83 (30)
Yang et al. (54) China Retrospective 93 (40) 46 Severe COVID-19 24 (26)
Yang et al. (55) China Retrospective 1,476 (47) 57 Mortality 238 (16)
Yang et al. (56) China Retrospective 52 (33) 60 Mortality 32 (62)
Zhang et al. (57) China Retrospective 221 (51) 55 Severe COVID-19 55 (25)
Zhang et al. (58) China Retrospective 663 (52) 56 Mortality 25 (4)
Zhang et al. (59) China Retrospective 140 (49) 57 Severe COVID-19 58 (41)
Zhang et al. (60) China Retrospective 120 (64) 45 Severe COVID-19 30 (25)
Zhang et al. (61) China Retrospective 115 (57) 50 Severe COVID-19 31 (27)
(Continued)
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TABLE 1 | Continued
Study Country Cohort type Total number of
patients (female %)
Age (year)‡ Outcome(s)
Definition Event number
(event rate %)
Zheng et al. (62) China Retrospective 161 (50) 45 Severe COVID-19 30 (19)
Zheng et al. (63) China Retrospective 96 (40) 55 Severe COVID-19 74 (77)
Zhou et al. (64) China Retrospective 191 (38) 56 Mortality 54 (28)
Zhou et al. (65) China Retrospective 15 (33) 62 Mortality 7 (47)
Zhou et al. (66) China Retrospective 21 (38) 66 ICU admission 13 (62)
COVID-19, coronavirus disease 2019; ICU, intensive care unit admission; NR, not reported.
†
Multiple countries (USA, Japan, Italy, Austria, France, Germany, Netherlands, Spain, and Canada); ‡mean or median.
TABLE 2 | Summary table of mortality, severe COVID-19, and intensive care unit requirement based on the HSROC analysis.
Prognostic factor No. of
studies
(no. of cases)
AUC
(95% CI)
Sensitivity
(95% CI)
I2 (%) Chi2 Specificity
(95% CI)
I2 (%) Chi2 PLR
(95% CI)
NLR
(95% CI)
Mortality
Liver failure 5 (3,523) 0.67 (0.63–0.71) 0.31 (0.12–0.59) 99 0.001 0.94 (0.71–0.99) 99 0.001 5.5 (1.6–19.4) 0.73 (0.55–0.97)
Platelet count 5 (3,259) 0.71 (0.67–0.75) 0.40 (0.23–0.59) 95 0.001 0.89 (0.75–0.96) 99 0.001 3.7 (1.5–9) 0.68 (0.5–0.91)
ALT 5 (2,127) 0.76 (0.72–0.79) 0.41 (0.30–0.53) 71 0.01 0.77 (0.75–0.80) 0 0.63 1.8 (1.4–2.4) 0.76 (0.64–0.92)
LDH 5 (2,149) 0.81 (0.78–0.85) 0.87 (0.74–0.94) 71 0.01 0.58 (0.41–0.73) 95 0.001 2.1 (1.4–3.1) 0.22 (0.1–0.48)
Intensive care unit requirement
Chronic liver disease 5 (831) 0.80 (0.77–0.84) 0.03 (0.01–0.06) 0 0.48 0.98 (0.96–0.99) 59 0.04 1.3 (0.5–3.3) 0.99 (0.97–1.02)
Platelet count 5 (628) 0.47 (0.43–0.52) 0.18 (0.11–0.28) 35 0.19 0.82 (0.72–0.89) 63 0.03 1 (0.6–1.6) 1 (0.9–1.12)
ALT 5 (1,190) 0.58 (0.54–0.62) 0.32 (0.25–0.41) 33 0.20 0.76 (0.70–0.81) 52 0.08 1.3 (1.1–1.7) 0.89 (0.81–0.98)
AST 6 (1,229) 0.65 (0.61–0.69) 0.55 (0.47–0.62) 37 0.16 0.69 (0.62–0.75) 78 0.001 1.7 (1.5–2.1) 0.66 (0.57–0.76)
CRP 6 (1,412) 0.75 (0.72–0.79) 0.92 (0.80–0.97) 88 0.001 0.31 (0.14–0.54) 95 0.001 1.3 (1.1–1.7) 0.27 (0.16–0.46)
Severe COVID-19
Chronic liver disease 10 (2,182) 0.65 (0.60–0.69) 0.03 (0.02–0.07) 75 0.001 0.97 (0.95–0.98) 76 0.001 1.2 (0.6–2.1) 1 (0.97–1.02)
Chronic hepatitis B 7 (3,911) 0.71 (0.67–0.75) 0.03 (0.01–0.08) 84 0.001 0.97 (0.95–0.98) 85 0.001 1.2 (0.6–2.4) 1 (0.97–1.02)
Platelet count 7 (1,868) 0.66 (0.62–0.70) 0.26 (0.15–0.42) 88 0.001 0.86 (0.77–0.91) 92 0.001 1.8 (1.2–2.7) 0.86 (0.75–0.99)
ALT 8 (1,625) 0.60 (0.55–0.64) 0.31 (0.19–0.48) 94 0.001 0.80 (0.66–0.89) 96 0.001 1.6 (1.1–2.2) 0.86 (0.74–0.99)
AST 9 (2,780) 0.70 (0.65–0.74) 0.40 (0.30–0.50) 88 0.001 0.84 (0.77–0.88) 90 0.001 2.4 (1.8–3.2) 0.72 (0.63–0.83)
LDH 9 (2,500) 0.75 (0.71–0.79) 0.67 (0.57–0.77) 93 0.001 0.72 (0.62–0.80) 95 0.001 2.4 (1.8–3.1) 0.45 (0.35–0.58)
CRP 6 (2,253) 0.68 (0.64–0.72) 0.91 (0.82–0.96) 89 0.001 0.34 (0.23–0.47) 94 0.001 1.4 (1.2–1.5) 0.27 (0.18–0.42)
COVID-19, coronavirus disease 2019; HSROC, hierarchical summary receiver-operating characteristic; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area
under the curve; CI, confidence interval; CRP, C-reactive protein; I2 and Chi2, heterogeneity; LDH, lactate dehydrogenase; NLR, negative likelihood ratio; PLR, positive likelihood ratio.
Diagnostic Metrics
For the prediction of mortality, a high specificity was
reached by liver failure (specificity: 0.94, 95% CI: 0.71–0.99)
and platelet count (specificity: 0.94, 95% CI: 0.71–0.99)
and a moderate sensitivity by LDH (sensitivity: 0.81,
95% CI: 0.78–0.85).
For the prediction of possible ICU requirement, CLD
(specificity: 0.98, 95% CI: 0.96–0.99) and platelet count
(specificity: 0.82, 95% CI: 0.72–0.89) proved to be specific,
whereas CRP was associated with high sensitivity (sensitivity:
0.92, 95% CI: 0.80–0.97).
For the prediction of severe disease course, CLD (specificity:
0.97, 95% CI: 0.95–0.98) and chronic hepatitis B infection
(specificity: 0.97, 95% CI: 0.95–0.98) were highly specific,
and platelet count (specificity: 0.86, 95% CI: 0.77–0.91), ALT
(specificity: 0.80, 95% CI: 0.66–0.89), and AST (specificity:
0.84, 95% CI: 0.77–0.88) were moderately specific, whereas
high sensitivity was reached by CRP (sensitivity: 0.91, 95%
CI: 0.82–0.96).
CLD for mortality and total bilirubin in case of severe
COVID-19 could not be analyzed because it was not feasible
despite the number of included studies.
Detailed results about the AUC, sensitivity, specificity,
likelihood ratios, and heterogeneity are shown in
Table 2. The HSROC curves are summarized in
Supplementary Figures 1–3.
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Analysis of the Strength of the Association
Liver failure (OR: 7.59; 95% CI: 1.84–31.30), platelet count (OR:
5.36; 95% CI: 1.28–22.37), albumin level (OR: 6.32; 95% CI: 1.40–
28.60), and ALT (OR: 2.49; 95% CI: 1.75–3.56), AST (OR: 5.39;
95% CI: 3.67–7.91), and LDH (OR: 9.23; 95% CI: 2.56–33.31)
activities were related to a high rate of mortality. CLD, hepatitis
B infection, and CRP concentration did not show significant
difference, considering mortality.
Albumin (OR: 3.79; 95% CI: 2.08–6.93), ALT (OR: 1.56; 95%
CI: 1.61–2.11), AST (OR: 2.53; 95% CI: 1.92–3.35), and LDH
(OR: 7.95; 95% CI: 4.54–13.92) levels and CRP (OR: 4.72; 95%
CI: 2.59–8.58) concentration were accompanied with high rate
of ICU admission. A significant difference could not be stated
regarding the need for ICU considering CLD, liver dysfunction,
and platelet count.
Fatty liver disease (OR: 3.86; 95% CI: 1.20–12.47), liver failure
(OR: 3.27; 95% CI: 1.20–8.87), total bilirubin (OR: 1.89; 95% CI:
1.35–2.63), platelet count (OR: 2.34; 95% CI: 1.53–3.58), albumin
level (OR: 3.11; 95% CI: 1.61–6.01), ALT (OR: 1.82; 95% CI:
1.18–2.81), AST (OR: 3.34; 95% CI: 2.37–4.71), LDH (OR: 5.02;
95% CI: 3.41–7.40), CRP (OR: 4.52; 95% CI: 3.16–6.49), and
GGT (OR: 3.03; 95% CI: 1.60–5.7) were accompanied with a
higher risk for more severe course. CLD, hepatitis B infection,
and elevated level of ALP did not show significant difference
concerning severity.
Results of the analysis of association and heterogeneity are
presented in Table 3. Forest plots for each analysis are shown in
Supplementary Figures 4–17.
Risk of Bias Assessment
Results of the risk of bias assessment between studies are shown
in Supplementary Table 5.
The assessment of publication bias could only be performed
in the case of CLD on severe COVID-19. It did not suggest the
presence of publication bias (p= 0.764).
DISCUSSION
This meta-analysis aimed to investigate the association between
pre-existing liver diseases and on-admission liver functions and
outcomes in COVID-19 infection, focusing on mortality, ICU
admission, and severe disease course (Figure 2). Considering
the prediction of mortality, liver failure and platelet count are
highly specific, whereas LDH is moderately sensitive. For the
prediction of ICU requirement, CLD was associated with high
specificity, platelet count with moderate specificity, and CRP
with high sensitivity. Regarding severe disease course, CLD and
chronic hepatitis B infection were proven to be highly specific,
and platelet count and ALT and AST activities were moderately
specific, whereas CRP was highly sensitive.
In relation to the investigated factors and poorer outcomes,
acute liver failure; platelet count; albumin level; ALT, AST, and
LDH activities; and CRP concentration were associated with
higher mortality. Albumin, ALT, AST, LDH, and CRP influenced
the admission to the ICU. Fatty liver disease, liver injury, total
bilirubin, ALT, AST, LDH, CRP, GGT, platelet count, and albumin
level were associated with more severe disease course.
The knowledge about the impact of liver-related comorbidities
in the clinical outcome of COVID-19 is limited. In line
with our results, an earlier meta-analysis concluded that CLD
is not associated with severity or mortality (67). However,
clinicians should be skeptical about it, because these patients
are more prone to infection due to cirrhosis-associated immune
dysfunction and are more likely to have poor outcomes from
ARDS (68, 69). This may account for the relatively low baseline
prevalence of CLD in the included patients, as one previous
meta-analysis suggests (70), or it was not well-reported. Further
on, in a recently published letter on the involvement of the
liver in COVID-19, the authors found an increased odds of
severe infection and mortality in patients with liver injury
(71). Another study analyzed the frequency of abnormal liver
function derangements in severe COVID-19 and concluded
that hypoalbuminemia followed by derangements in GGT and
aminotransferases were more frequent in severe disease (72). On
the other hand, another study highlights that digestive symptoms
and liver injury are not uncommon in patients with SARS-CoV-2
infection (73).
Dysregulated hepatic immune responses caused by metabolic
associated fatty liver disease (MAFLD) may contribute to
cytokine storm in younger patients (74), whereas chronic low
grade inflammation known to be associated with MAFLD
may worsen outcome. Post-mortem liver biopsy showed
overactivation of T cells in the liver, and liver injury is likely
mediated by immune response rather than direct cytopathic
damage (35).
Compared with previous results (12, 75, 76), our study
reasserts that in severe forms of COVID-19, alterations of on-
admission level of the liver enzymes can be observed, probably
due to the virally induced cytotoxic T cells and the innate
immune response against the virus. Another reason behind
the liver test abnormalities in COVID-19 patients could be
the cholangiocyte dysfunction due to direct infection of bile
duct cells via angiotensin-converting enzyme 2 receptor (8).
However, according to our results, ALP does not seem to
be a significant predictive marker in COVID-19. Additionally,
moderate microvesicular steatosis, mild lobular, and portal
activity can be observed in the pathological samples of patients
who died from COVID-19 (77).
Despite the lack of coagulation factors in liver diseases,
a hypercoagulable state could also be present in COVID-
19. A recent study concluded that COVID-19 disease has
prominent manifestations from the hematopoietic system and
is often associated with a major blood hypercoagulability (78).
In histopathological findings, it was highlighted that extensive
vascular portal and sinusoidal thrombosis could lead to abnormal
high level of transaminases (79).
Considering the strengths of our meta-analysis, a rigorous
methodology was followed. To our knowledge, this is the
first study that addresses the prognostic value of on-admission
liver parameters, underlying liver comorbidities, and COVID-
19 induced hepatic failure on the level of sensitivity and
specificity. On the other hand, our study has several limitations.
We only included cohort studies that mostly originate from
Asia, which might carry a high risk of bias. The definitions
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TABLE 3 | Summary of findings.
Prognostic factor Mortality Intensive care unit requirement Severe COVID-19
No. of studies
(no. of pts)
Odds ratio
(95% CI)
I2 (%) Chi2 No. of studies
(no. of pts)
Odds ratio
(95% CI)
I2 (%) Chi2 No. of studies
(no. of pts)
Odds ratio
(95% CI)
I2 (%) Chi2
Chronic liver disease 4 (646)† 1.5 (0.42–5.41) 0 0.54 5 (831) 1.42 (0.56–3.63) 0 0.72 10 (2,182) 1.45 (0.87–2.42) 0 0.7
Liver dysfunction 2 (145) 1.13 (0.36–3.58) 0 0.33 2 (384) 1.77 (0.62–5.06) 0 0.98 2 (163) 1.11 (0.36–3.47) 0 0.56
Chronic hepatitis B 2 (1,864) 1.18 (0.42–3.34) 0 0.97 1 (1,590) 0.55 (0.07–4.11) NR NR 7 (3,911) 1,55 (0.85–2.83) 13 0.33
Fatty liver disease NR NR NR NR NR NR NR NR 4 (964) 3.86 (1.2–12.47)* 79 0
Liver failure 5 (3,523) 7.59 (1.84–31.30)* 91 0 1 (43) 1.88 (0.47–7.54) NR NR 4 (1,185) 3.27 (1.2–8.87)* 70 0.02
Total bilirubin 1 (975) 5 (2.48–10.07)* NR NR 2 (395) 1.66 (0.45–6.06) 33 0.22 6 (2,059) 1.89 (1.35–2.63)* 0 0.57
Platelet count 5 (3,259) 5.36 (1.28–22.37)* 95 0 5 (628) 0.95 (0.63–1.44) 0 0.79 7 (1,868) 2.34 (1.53–3.58)* 46 0.09
International normalized ratio NR NR NR NR 1 (20) 5 (0.18–139.17) NR NR 1 (115) 0.72 (0.31–1.66) NR NR
Albumin 3 (944) 6.32 (1.4–28.6)* 63 0.07 3 (744) 3.79 (2.08–6.93)* 0 0.81 4 (1,205) 3.11 (1.61–6.01)* 69 0.02
Alanine aminotransferase 5 (2,127) 2.49 (1.75–3.56)* 10 0.35 5 (1,190) 1.56 (1.16–2.11)* 0 0.99 8 (1,625) 1.82 (1.18–2.81)* 70 0
Aspartate aminotransferase 4 (1,966) 5.39 (3.67–7.91)* 0 0.63 6 (1,229) 2.53 (1.92–3.35)* 0 0.48 9 (2,780) 3.34 (2.37–4.71)* 60 0.01
Lactate dehydrogenase 5 (2,149) 9.23 (2.56–33.31)* 85 0 4 (748) 7.95 (4.54–13.92)* 0 0.75 9 (2,500) 5.02 (3.41–7.4)* 66 0
C-reactive protein 4 (1,846) 9.19 (0.84–100.63) 77 0 6 (1,412) 4.72 (2.59–8.58)* 35 0.17 6 (2,253) f4.52 (3.16–6.49)* 31 0.21
Alkaline phosphatase NR NR NR NR 1 (19) 0.11 (0–2.73) NR NR 4 (623) 1.71 (0.66–4.46) 24 0.27
Gamma-glutamyl transferase NR NR NR NR 1 (19) 1.39 (0.22–8.92) NR NR 3 (635) 3.03 (1.6–5.72)* 50 0.14
CI, confidence interval; COVID-19, coronavirus disease 2019; I2 and Chi2, heterogeneity; NR, not reported.
*p < 0.05;
†
one study could not be included in the analysis, because there were no events.
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FIGURE 2 | Summary of findings. ALI, acute liver injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; CRP,
C-reactive protein; FLD, fatty liver disease; GGT, gamma-glutamyl transferase; ICU, intensive care unit; LDH, lactate dehydrogenase; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2; TBIL, total bilirubin.
of the investigated outcomes were not uniform among the
included reports; to estimate this problem, we applied a
modified QUIPS. The cut-off values of laboratory parameters
and the definition of liver diseases (Supplementary Tables 6,
7) were also slightly different among articles, causing probably
significant heterogeneity in our analysis. However, the different
laboratory methodologies among the centers might justify
this difference. Furthermore, previous drug treatment before
admission of COVID-19 was not investigated. Multivariate
analysis was not applied; thus, the investigated prognostic factors
should not be regarded as independent risk factors. This all
could contribute to the significant heterogeneity in some of
our results.
Implication for Practice
The establishment of a prognostic score assessing the possible
outcomes of patients suffering from any liver pathology
is needed. This meta-analysis succeeded to identify some
factors, with high specificity, which might be a footstone
for such a prognostic tool that might be completed by
additionally recognized risk factors, for example, elevated
absolute white blood cell count, decreased lymphocyte count,
and elevated interleukin-6 and serum ferritin concentrations
(80). Patients who are affected by the underlying liver pathology
might need advanced therapy earlier to avoid undesired
clinical outcomes.
Implication for Research
Based on our results and previously published analyses, further
basic research is crucial for a better understanding of the
liver injury caused by COVID-19, hepatic comorbidities, and
treatment itself.
CONCLUSION
In conclusion, on-admission platelet count, ALT and AST
activities, CRP concentration, and the presence of acute and
CLDs predicted the severe course of COVID-19. To highlight,
investigating hepatic injury associated by SARS-CoV-2 infection
may play an important role in the prediction of mortality and
may be used for the establishment of prognostic tools to identify
patients with possible poorer outcomes.
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